# Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

> **NCT02575950** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 59 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** LEO43204
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02575950
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02575950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02575950, "Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02575950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*